Fig. 6

USP39 expression levels as potential predictors of immune checkpoint blockade (ICB) response in pancreatic adenocarcinoma (PAAD). (A) Heatmap illustrating differential enrichment scores of immune-related signature pathways between USP39 high- and low-expression groups. (B-C) Comparative analysis of enrichment scores for immunotherapy-predicted pathways and cancer-immunity cycle pathways between USP39 expression groups. (D-F) Correlation analyses between USP39 expression and (D) immunotherapy-predicted pathway enrichment scores, (E) cancer immunity cycle steps, and (F) immune checkpoint marker expression. (G) Analysis of predicted immunotherapy responsiveness between USP39 expression groups in TCGA-PAAD cohort using SubMap analysis (GenePattern database). (H) Evaluation of immunotherapy response in the IMvigor210 cohort comparing high- versus low-USP39 expression groups. (I) Comparative analysis of macrophage regulation and TGF-β response pathway activities between USP39 expression groups based on CAMOIP database. *P < 0.05, **P < 0.01, ***P < 0.001